Atıf İçin Kopyala
ALİ R., ÖZKALEMKAŞ F., Kimya Y., Koksal N., ÖZKOCAMAN V., Gulten T., ...Daha Fazla
ARCHIVES OF GYNECOLOGY AND OBSTETRICS, cilt.280, sa.2, ss.169-175, 2009 (SCI-Expanded)
-
Yayın Türü:
Makale / Derleme
-
Cilt numarası:
280
Sayı:
2
-
Basım Tarihi:
2009
-
Doi Numarası:
10.1007/s00404-008-0861-7
-
Dergi Adı:
ARCHIVES OF GYNECOLOGY AND OBSTETRICS
-
Derginin Tarandığı İndeksler:
Science Citation Index Expanded (SCI-EXPANDED), Scopus
-
Sayfa Sayıları:
ss.169-175
-
Anahtar Kelimeler:
Imatinib, Chronic myeloid leukemia, CML, Cancer, Pregnancy, Breast milk, Umbilical cord blood, Infant peripheral blood, Targeted therapy, CHRONIC MYELOID-LEUKEMIA, PATIENT, ISSUES, CML, LEUKAPHERESIS, MANAGEMENT, MESYLATE, CANCER, SAFETY
-
Bursa Uludağ Üniversitesi Adresli:
Evet
Özet
The development of imatinib as a therapeutic agent targeting BCR-ABL has increased the treatment options for chronic myeloid leukemia (CML) by significantly impacting outcomes, and imatinib is recommended by treatment guidelines as the first-line therapy. However, treatment of maternal CML with imatinib during gestation is not recommended because of the potential risk to the fetus.